Table 6.

Effects of the ANGPTL4 rs4076317 SNP on serum lipid levels at baseline and response to atorvastatin therapy in hyperlipidemia

Group	TC (mmol/L)	TG (mmol/L)	HDL-C (mmol/L)	LDL-C (mmol/L)	ApoA1(g/L)	ApoB(g/L)
Total patient (n = 724)
Before	5.33±1.01	2.12±1.39	1.44±0.61	3.17±0.93	1.19±0.35	1.04±0.23
After	4.41±0.46	1.05±0.32	1.48±0.49	2.59±0.46	1.01±0.23	0.81±0.15
F	22.305	20.185	1.376	15.042	11.565	22.538
P	0.000	0.000	0.169	0.000	0.000	0.000
Control (n = 253)
Before	5.62±0.71	1.74±1.51	1.98±0.54	3.24±0.72	1.47±0.25	1.03±0.19
After	4.67±0.30	0.96±0.31	1.93±0.43	2.61±0.40	1.42±0.21	0.87±0.13
F	19.604	8.049	1.152	12.166	2.436	11.055
P	0.000	0.000	0.250	0.000	0.015	0.000
CAD (n = 248)
Before	5.14±1.16	2.29±1.18	1.13±0.35	3.08±1.08	1.06±0.35	1.05±0.28
After	4.29±0.48	1.12±0.31	1.20±0.31	2.61±0.52	0.97±0.25	0.78±0.16
F	10.663	15.102	2.358	6.175	3.295	13.185
P	0.000	0.000	0.019	0.000	0.001	0.000
IS (n = 223)
Before	5.22±1.02	2.36±1.37	1.18±0.49	3.19±0.96	1.03±0.21	1.06±0.22
After	4.26±0.47	1.08±0.32	1.30±0.31	2.53±0.45	1.04±0.21	0.82±0.15
F	12.765	13.587	3.091	9.296	0.503	13.460
P	0.000	0.000	0.002	0.000	0.615	0.000
CC genotype (n = 381)
Before	5.34±0.95	2.18±1.50	1.45±0.61	3.15±0.89	1.20±0.36	1.03±0.21
After	4.56±0.40	1.07±0.31	1.52±0.49	2.70±0.44	1.04±0.24	0.82±0.15
F	14.770	14.145	1.746	8.847	7.218	15.883
P	0.000	0.000	0.081	0.000	0.000	0.000
CG genotype (n = 284)
Before	5.29±1.00	2.04±1.11	1.42±0.63	3.18±0.94	1.19±0.34	1.06±0.25
After	4.26±0.45	1.06±0.33	1.43±0.49	2.48±0.44	1.14±0.29	0.80±0.17
F	15.829	14.262	0.211	11.366	1.886	14.493
P	0.000	0.000	0.833	0.000	0.060	0.000
GG genotype (n = 59)
Before	5.49±1.18	2.12±1.78	1.43±0.48	3.21±1.06	1.16±0.28	1.04±0.26
After	4.18±0.59	0.95±0.31	1.48±0.50	2.40±0.49	1.14±0.29	0.81±0.14
F	7.627	4.974	0.554	5.327	0.381	5.983
P	0.000	0.000	0.581	0.000	0.704	0.000

TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA1 apolipoprotein A1, ApoB apolipoprotein B